Villya Pharmaceuticals, based in Melbourne, Florida, is excited to announce the granting of U.S. Patent No. 12,115,222 B2, titled “Compositions and Methods for Improving the Solubility of Erectile Dysfunction Therapeutics.” This patent marks a pivotal advancement in the pharmaceutical industry, specifically in the treatment of erectile dysfunction (ED).
https://mma.prnewswire.com/media/2616996/Villya_Pharmaceuticals_Logo.jpg
The innovative method outlined in the patent enhances the solubility of poorly water-soluble ED drugs like alprostadil, sildenafil, tadalafil, vardenafil, and avanafil by combining them with Villya's technology to form a water-soluble drug-complex. This approach represents a revolutionary method of drug loading through carbohydrates, which the human body absorbs efficiently.
This breakthrough is anticipated to increase the bioavailabilityof these medications, potentially allowing for lower dosages, fewer side effects, and improved patient compliance and treatment outcomes. Enhanced solubility ensures that these drugs can be absorbed more effectively, leading to quicker and more consistent therapeutic results.
Preliminary rat studies have demonstrated that Villya's second-generation sildenafil loads within 3-5 minutes and exhibits a secondary release approximately one to one-and-a-half hours later, with an overall pharmacokinetic (PK) profileof 4 hours when administered orally. When given sublingually, the PK profile shows loading in 3-5 minutes with multiple releases over six hours. As a subcutaneous (SQ) injection, it loads within 3-5 minutes with a high initial PK release, followed by a therapeutic dose over 24 hours. This versatility allows Villya to customize the medication to meet specific therapeutic needs.
William Miller, CEO of Villya Pharmaceuticals, commented, “This patent reflects our dedication to innovative healthcare solutions. By enhancing the solubility of these drugs, we can deliver treatments that are both more effective and accessible for patients.”
Villya Pharmaceuticals is exploring partnerships and licensing opportunities to either bring this technology to market or commence production itself. We are planning for the product to be domestically manufactured within the United States.
For more information about this patent, please contact:
Villya PharmaceuticalsEmail: info@villya.net
About Villya PharmaceuticalsVillya Pharmaceuticals, located in Melbourne, FL, focuses on developing innovative drug delivery systemsand new therapeutic solutions aimed at improving patient outcomes across various medical fields. Led by CEO William Miller, Villya is dedicated to enhancing lives through scientific innovation, right here in the USA
https://mma.prnewswire.com/media/2616997/William_Miller.jpg
https://c212.net/c/img/favicon.png?sn=FL15948&sd=2025-02-11
View original content to download multimedia:https://www.prnewswire.com/news-releases/in-response-to-president-trumps-request-to-bring-pharmaceutical-production-back-to-america-villya-pharmaceuticals-announces-breakthrough-patent-for-enhancing-solubility-of-medications-302372856.html
SOURCE Villya Pharmaceuticals
https://rt.newswire.ca/rt.gif?NewsItemId=FL15948&Transmission_Id=202502111000PR_NEWS_USPR_____FL15948&DateId=20250211